Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Hoffmann-Vold (Oslo, Norway), T. Maher (London, United Kingdom), E. Philpot (Durham, NC, United States of America), A. Ashrafzadeh (San Diego, CA, United States of America), O. Distler (Zurich, Switzerland), M. Kreuter (Heidelberg, Germany). Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis. 5195

Member's Comments

No comment yet.

Related content which might interest you: Clinical use of interstitial lung disease guidelines Source: Eur Respir Mon; 2009: 46: 386–395 Year: 2009 Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review Source: ERJ Open Res, 7 (1) 00235-2020; 10.1183/23120541.00235-2020 Year: 2021 Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines Source: Eur Respir Rev 2014; 23:193-214 Year: 2014 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011 Source: Eur Respir J 2011; 37: 743-746 Year: 2011 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management Source: Guideline 2016 Year: 2016 Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management Source: Eur Respir J 2016; 47: 45-68 Year: 2016 Can current guidelines improve the diagnosis of a usual interstitial pneumonia among general radiologists? Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Evidence-based treatment strategies in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 163-168 Year: 2013 A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease Source: Eur Respir J, 58 (6) 2100276; 10.1183/13993003.00276-2021 Year: 2021 Current challenges in diagnosing and treating adults with interstitial lung disease Source: International Congress 2014 – PG01 Challenges faced when diagnosing idiopathic interstitial lung disease Year: 2014 The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF Source: Eur Respir J 2015; 46: 883-886 Year: 2015 Clinical management of the idiopathic interstitial pneumonias: an example of an integrated approach to interstitial lung diseases Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias Year: 2006 Diagnosis of interstitial lung diseases and impact of guidelines: an issue only for pulmonologists? Source: Annual Congress 2007 - Controversies in the management of interstitial lung diseases Year: 2007 Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis Source: Eur Respir J, 54 (2) 1900586; 10.1183/13993003.00586-2019 Year: 2019 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Imaging of idiopathic pulmonary fibrosis based on case presentations: guidelines, pitfalls and prevention of misdiagnosis Source: Virtual Congress 2021 – Imaging grand round Year: 2021 Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence Source: Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018 Year: 2018